Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 3, 2010, Pages 210-214

  Chen, Kun ^a   Fields, Theodore ^a   Mancuso, Carol A ^a   Bass, Anne R ^a   Vasanth, Lisa ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Anakinra; Arthritis; Efficacy; Gout

Indexed keywords

ALLOPURINOL; BETAMETHASONE; COLCHICINE; CORTICOSTEROID; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; URATE;

ACUTE DISEASE; ADULT; AGED; CLINICAL ARTICLE; COMORBIDITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GOUT; HEMODIALYSIS; HUMAN; INJECTION SITE REACTION; KIDNEY FAILURE; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SHORT COURSE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GOUT; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78649445097     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.03.001     Document Type: Review

References (23)

1. McCarty D.J. Crystals and arthritis. Dis Mon 1994, 40(6):255-299.
2. Choi H. Epidemiology of crystal arthropathy. Rheum Dis Clin North Am 2006, 32(2):255-273. v.
3. Groff G.D., Franck W.A., Raddatz D.A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990, 19(6):329-336.
4. Man C.Y., Cheung I.T., Cameron P.A., Rainer T.H. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007, 49(5):670-677.
5. Janssens H.J., Janssen M., van de Lisdonk E.H., van Riel P.L., van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008, 371(9627):1854-1860.
6. Fels E., Sundy J.S. Refractory gout: what is it and what to do about it?. Curr Opin Rheumatol 2008, 20(2):198-202.
7. Saag K.G., Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006, 8(Suppl 1):S2.
8. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440(7081):237-241.
9. Martin W.J., Walton M., Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 2009, 60(1):281-289.
10. Taniguchi S., Sagara J. Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein, ASC. Semin Immunopathol 2007, 29(3):231-238.
11. Jacques C., Gosset M., Berenbaum F., Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006, 74:371-403.
12. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996, 39(7):1092-1101.
13. Gratton S.B., Scalapino K.J., Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009, 61(9):1268-1270.
14. Singh D., Huston K.K. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 2009, 15(7):366.
15. McGonagle D., Tan A.L., Shankaranarayana S., Madden J., Emery P., McDermott M.F. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66(12):1683-1684.
16. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9(2):R28.
17. Wallace S.L., Robinson H., Masi A.T., Decker J.L., McCarty D.J., Yu T.F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20(3):895-900.
18. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48(4):927-934.
19. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41(12):2196-2204.
20. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58(8):2443-2452.
21. So A., Meulemeester M., Shamim T., Pikhlak A., Yucel E., Arulmani U., et al. Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to NSAIDs and/or colchicine. ACR 2009, Abstract LB4.
22. Schumacher H.R., Sundy J.S., Terkeltaub R., Knapp H.R., Mellis S., Soo Y., et al. Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy [Abstract]. Arthritis Rheum 2009, 60(Suppl 10):1096.
23. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68(10):1613-1617.